Imprimis Pharmaceuticals acquires the intellectual property rights for ophthalmic compound from Novel Drug Solutions


Imprimis Pharmaceuticals (IMMY -4.7%) acquires the intellectual property, including a provisional patent application, related to an ophthalmic compound for intraoperative ocular injection of anti-inflammatory and anti-bacterial agents from Novel Drug Solutions.

The target compound, referred to as IPI-140, is based on a combination of moxifloxacin and triamcinolone.

IMMY says it believes the formulation has the potential to "impact the fast-growing $5B global cataract surgery drug market."

Additionally, the deal gives IMMY preemptive rights to other Novel Drug Solutions and Eye Care Northwest intellectual property and drug development opportunities.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs